Citations

Clear

623 citation(s) found for "Torres, V".

Small nucleolar RNAs (snoRNAs) expression and effects on patient (pt) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB (Alliance)/SWOG 80405.
Millstein, Joshua , Bartolini, Michela, Ashouri, Karam , Algaze, Sandra, Torres‐Gonzalez, Lesly , Shah, Unnati Hermant, Zhang, Wu, Innocenti, Federico , Lenz, Heinz‐Josef , Battaglin, Francesca , Soni, Shivani , Algaze, Sandra , Mittal, Pooja , Jayachandran, Priya , Shah, Unnati Hermant, Ou, Fang‐Shu , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3145-3145

10.1200/jco.2025.43.16_suppl.3145 Get It

3145 Background: SnoRNAs are non-coding RNAs that primarily guide the chemical modification of ribosomal RNA. Emerging evidence suggests snoRNAs play critical roles in cancer, including CRC, by regulating cell proliferation, apoptosis and tumor progression. Aberrant snoRNA expression has been linked to CRC development and poor prognosis, offering potential as diagnostic biomarkers and therapeutic targets. We investigated whether the tumor expression levels of 3 types of snoRNAs (SCARNA, SNORA, SNORD) affect treatment response in pts enrolled in CALGB/SWOG 80405 (NCT00265850). Methods: 433 mCRC pts treated with bevacizumab (bev, n = 226) or cetuximab (cet, n = 207) in combination with first-line chemotherapy were analyzed. RNA was isolated from FFPE tumor samples and sequenced on the HiSeq 2500 (Illumina). 422 snoRNAs were evaluated (23 SCARNA, 140 SNORA, 259 SNORD). Overall survival (OS) and progression-free survival (PFS) were compared across tertiles of gene expression (high [H], medium [M], low [L]) by multivariable Cox proportional hazards models adjusted for age, sex, ECOG performance status, tumor side, number of metastatic sites, KRAS , CMS subtypes, and treatment. Interaction tests for the predictive effect (bev vs cet) were performed. P -values were corrected for multiple testing using the Benjamini-Hochberg approach ( q < 0.05). Results: Only SCARNA21 achieved statistical significance for OS after false discovery rate (FDR) adjustment. Tumors with H levels of SCARNA21 had shorter survival compared to tumors with M or L expression (median OS 24.4 vs 32.4 vs 33.9 months, respectively; P = 0.0015, q = 0.033), independent of treatment. No snoRNAs achieved FDR significance for PFS. However, several snoRNAs showed significant treatment interactions with biologic agents. SCARNA6-H and SCARNA5-H tumors had longer PFS and OS when treated with cet, but shorter PFS and OS when treated with bev, compared to the M and L expression groups (PFS interaction q = 0.0067 and 0.045, respectively; OS interaction q = 0.022 and 0.034, respectively). SCARNA7 also showed significant treatment interaction for OS, favoring cet in the H expression group ( q = 0.018); the opposite was observed for SNORA63B, SNORA63D, SNORA35B, and SNORA36C ( q = 0.027, 0.027, 0.027 and 0.047, respectively). No significant results were observed for any of the tested SNORDs. Conclusions: SnoRNAs dysregulation affects key pathways such as cell cycle control and immune evasion, making them promising players in CRC biology. Our study highlights the prognostic and predictive potential of specific snoRNAs in mCRC. Notably, high SCARNA21 expression was linked to shorter OS, while SCARNA5 and 6 showed predictive value for treatment response, indicating their potential for guiding treatment decisions. Further validation is needed to confirm these findings, and mechanistic studies are warranted.
Long non-coding RNA (lncRNA) SNHG11 as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC): Insights from CALGB (Alliance)/SWOG 80405.
Bartolini, Michela, Millstein, Joshua , Mittal, Pooja, Algaze, Sandra, Ashouri, Karam , Torres‐Gonzalez, Lesly , Shah, Unnati Hermant, Innocenti, Federico , Lenz, Heinz‐Josef , Battaglin, Francesca , Ou, Fang‐Shu , Soni, Shivani , Mittal, Pooja , Algaze, Sandra , Shah, Unnati Hermant, Jayachandran, Priya , Zhang, Wu , Venook, Alan P. , Puccini, Alberto

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3128-3128

10.1200/jco.2025.43.16_suppl.3128 Get It

3128 Background: LncRNAs have emerged as key regulators of cancer progression and therapeutic responses. In CRC, several lncRNAs have been implicated in modulating tumor growth, metastasis and treatment resistance by interacting with critical tumorigenic pathways. Here, we investigate the potential prognostic and predictive value of lncRNA expression in patients (pts) with mCRC enrolled in CALGB/SWOG 80405 (NCT00265850) trial. Methods: We analyzed 433 mCRC pts treated with either bevacizumab (bev, n = 226) or cetuximab (cet, n = 207) plus first-line chemotherapy. Tumor RNA expression (Illumina HiSeq 2500) of 13 candidate lncRNAs (SNHG11, HOTAIR, FGF14-AS2, H19, YWHAE, NEAT1, MIR100HG, UCA1, LINC00973, SLCO4A1-AS1, POU5F1P4, MALAT1, HCG18) was explored. Median overall survival (mOS) and progression-free survival (mPFS) in months (mo) were compared between pts grouped by tertiles (low [L] vs medium [M] vs high [H]) of gene expression. Likelihood ratio tests, hazard ratios and 95% confidence intervals were computed from multivariable Cox proportional hazards models, adjusting for age, sex, ECOG PS, tumor location, number of metastatic sites, KRAS , Consensus Molecular Subtypes (CMS), and treatment. Results: Overall, SNHG11 was strongly associated with OS and PFS after adjusting for multiple tests (Benjamini-Hochberg False Discovery Rate < 0.05). High SNHG11 expression (H group, n = 144) was associated with improved mPFS (H: 14.3 vs M: 11.2 vs L: 8.3 mo; p = 0.038) and mOS (H: 39.6 vs M: 31.1 vs L: 20.5 mo; p = 0.033) in the combined treatment analysis. Among cet-treated pts, SNHG11-H showed a numerically longer mPFS (H: 14.2 vs M: 11.1 vs L: 7.6 mo; p = 0.19) and significantly longer mOS (H: 41.1 vs M: 32.4 vs L: 14.3 mo; p = 0.012). In contrast, no statistically significant OS or PFS differences were observed in bev-treated pts. SNHG11-H tumors had a significant OS benefit from cet compared to bev (mOS 41.1 vs 36.5 mo, respectively; p = 0.016), with a nominally significant treatment interaction observed for OS (p = 0.030). No significant differences were observed in the L or M expression groups. Additional analyses showed that SNHG11 expression was high in the CMS2 (canonical) subtype and substantially lower in CMS1 (immune). Conclusions: LncRNA SNHG11 plays a significant role in CRC progression and metastasis via tumorigenic pathways, including c-Myc and HIF-1α. Moreover, elevated circulating SNHG11 levels show promise as a non-invasive biomarker for early CRC detection. In CALGB/SWOG 80405, high SNHG11 expression correlated with improved PFS and OS, particularly in cet-treated pts, supporting its role as a prognostic and predictive biomarker. Its strong association with CMS2 aligns with its reported involvement in c-Myc-driven pathways. Further validation is needed to confirm the clinical utility of this biomarker and elucidate underlying mechanisms.
The effect of aspirin on aneurysm wall enhancement: A study in rabbits and humans
Sagues, Elena , Gudino, Andres, Dier, Carlos , Shenoy, Navami , Saleem, Arshaq , Kadirvel, Ramanathan , Sanchez, Sebastian , Torres, M. de, Gudino, Andres , Dier, Carlos , Shenoy, Navami , Saleem, Arshaq , Kadirvel, Ram , Lehman, Vance T. , Samaniego, Edgar A , Ojeda, Diego, Torres, Maria B, Hasan, David

Mayo Clinic

Interventional Neuroradiology | May 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251341035 | PMID 40356451 Get It

Objective Aneurysm wall enhancement (AWE) is a potential biomarker of inflammation within the aneurysm wall that has been correlated with a higher risk of rupture. Aspirin (ASA) may decrease AWE due to its anti-inflammatory properties. We aimed to assess the effect of ASA on AWE in an animal model and a cohort of patients with unruptured intracranial aneurysms (UIAs). Methods Three rabbits with elastase-induced aneurysms were exposed to ASA for 8 weeks and three rabbits were used as controls. 3 T high-resolution magnetic resonance imaging (HR-MRI) was performed at 7 days and 8 weeks to evaluate changes in AWE through histological and immunohistological analyses. Additionally, we evaluated AWE in patients who underwent imaging with a 3 T HR-MRI protocol. ASA exposure was defined as daily intake of 81 mg for at least six months prior to HR-MRI. AWE was quantified using three-dimensional AWE maps and histograms. Results Among rabbits exposed to ASA, the mean AWE was lower at 8 weeks compared to the controls (2.11 vs 2.15, p = 0.13). Immunostaining of the aneurysm wall in rabbits that received ASA revealed a reduced expression of CD68 + or cyclooxygenase-2 + cells, compared to the controls. A total of 99 patients with 120 UIAs were included in the HR-MRI analysis of UIAs. UIAs exposed to ASA (22/120) had significantly lower median AWE than those that were not exposed (0.60 vs 0.72, p = 0.032). Conclusion ASA therapy is associated with an objective reduction in AWE, suggesting a potential role in lowering the risk of aneurysm rupture.
Vasopressin V1a and V1b receptor antagonism does not affect the efficacy of tolvaptan in polycystic kidney disease
Nanayakkara, K.D.L. , Hu, Jinghua , Nanayakkara, Kavini , Hu, Jinghua , Torres, Vicente E , Wang, Xiaofang , Li, Jiang , Torres, Vicente E.

Mayo Clinic

American Journal of Physiology-Renal Physiology | May 26, 2025 | Volume: 329 | Issue: 1 | Pages: F20-F31

10.1152/ajprenal.00350.2024 | PMID 40418559 Get It

Currently, the vasopressin V2 receptor antagonist tolvaptan is the only approved treatment for autosomal dominant polycystic kidney disease (ADPKD). It has been suggested that vasopressin acting on V1a or V1b receptors may also affect its development. We show that a V1aR antagonist has no effect in an ADPKD mouse model (Pkd1RC/RC), whereas a V2R antagonist has a modest attenuating effect in female mice only. Neither potentiates or hinders the beneficial effect of tolvaptan when administered in combination with this drug.
Trends in Patch Test Results With the Mayo Clinic Extended Standard Series: A 14-Year Retrospective Review (2010–2023)
Aristizabal-Torres, Miguel A., Youssef, Molly J. , Yang, Yul W. , Yiannias, James A. , Davis, Mark D.P. , Hall, Matthew R. , Torres, Miguel A. Aristizabal , Aristizabal, Miguel A , Youssef, Molly, Aristizabal, Miguel

Mayo Clinic

Dermatitis® | May 14, 2025 | Volume: 37 | Issue: 2 | Pages: 230-237

10.1089/derm.2025.0075 | PMID 40365644 Get It

Abstract: Background: Extended patch testing beyond the standard series is commonly performed in patients with allergic contact dermatitis. This broader testing allows for more precise and complete allergen identification, ultimately leading to improved clinical outcomes. Objective: To report the Mayo Clinic Contact Dermatitis Group (MCCDG) patch testing results using a custom extended series from 2010 to 2023. Methods: A retrospective review of patch testing results using the MCCDG extended standard series at the Mayo Clinic was conducted. Data from 2010 to 2023 were analyzed. Results: Patch testing with the extended standard series was performed in 3,767 unique patients, with a total of 3834 extended standard patch tests administered (81.8% in women, 18.2% in men). The top 5 allergens eliciting positive reactions were gold (I) sodium thiosulfate (10.4%), benzisothiazolinone (10.4%), carmine (9.4%), thimerosal (9.3%), and hydroperoxides of linalool (8.8%). Conclusions: The extended standard series expands the diagnostic scope for patients in whom the standard series incompletely identifies relevant allergens. Preservatives and fragrances remain among the most common sensitizers, emphasizing the need for ongoing allergen surveillance, periodic review, and updates to patch test series to enhance diagnostic accuracy and patient care.
Short-course Versus Long-course Antibiotic Treatment for Ventilator-associated Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Singh, Harsimran , Fite, Amsalu, Farooqi, M., Antil, Priya, Tammineedi, Sai Niharika , Gami, NK, Komminni, Praveen Kumar , Taqi, Batoul Ali, Shaikh, Safia , Sahra, Syeda , Faran, Anna, Ahmad, Faran , Singh, H., Farooqi, M., Kakish, Diala Ra’Ed Kamal , Ahmed, Muhammad Saad , Gami, N., Shaikh, S.R.A., Cheema, Huzaifa Ahmad , Ahmad, Sharjeel , Faran, A., Torres, Antoní

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3719-A3719

10.1164/ajrccm.2025.211.abstracts.a3719 Get It

Abstract Rationale: Current guidelines recommend a short course of antibiotic therapy for ventilator-associated pneumonia (VAP) caused by non-fermenting gram-negative bacilli (NF-GNB). However, this approach has been associated with an increased risk of pneumonia recurrence. This meta-analysis aims to address inconsistencies in the literature and evaluate the efficacy of short-course versus long-course antibiotic therapy for VAP, particularly in cases due to NF- GNB. Methods: We systematically searched PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing short versus long courses of antibiotic therapy in patients with VAP. The primary outcomes were the risk of all-cause mortality and pneumonia recurrence. Data were analyzed using RevMan 5.4, with risk ratio (RR) and mean difference (MD) as effect measures. Results: Our pooled analysis included seven RCTs. There was no significant difference in all- cause mortality between short- and long-course antibiotic regimens (RR 1.02; 95% CI: 0.88-1.18; Figure 1). However, a short course of antibiotics increased the incidence ofpneumonia recurrence, particularly in patients with VAP due to NF-GNB (RR 1.64; 95% CI: 1.18-2.29; Figure 1). There were no significant differences between the two regimens regarding the duration of mechanical ventilation (MD 0.01 days; 95% CI: -0.51 to 0.53 days), ICU (MD 0.10 days; 95% CI: -1.00 to 1.20 days) and hospital stay (MD -0.63 days; 95% CI: -3.18 to 1.91 days), or subsequent infection with or acquisition of resistant organisms (RR 0.89; 95% CI: 0.63-1.24). Conclusions: Our meta-analysis suggests that while a short course of antibiotics increases the risk of pneumonia recurrence in NF-GNB VAP, it does not impact mortality compared to a longer course. The clinical significance of the increased recurrence of pneumonia remains uncertain, as it did not result in worse clinical outcomes. A practical approach incorporating validated clinical criteria and biomarker thresholds to guide the duration of antibiotic therapy may be more effective for patients with NF-GNB VAP. Larger RCTs are needed to drawdefinitive conclusions in this population.
Dipnech: Clinical Characteristics of an International Case Series
O'Brien, H., O’Callaghan, Michael , Penugonda, M., Almeamar, Hussein , Samhouri, Bilal F. , Veltkamp, Marcel , Manali, Effrosyni D. , Lazaratou, A., Papiris, Spiridon, Carr, Laurie, Kolilekas, Lykourgos , Daniil, Z., Hernández‐González, Fernanda , Torres, J. Sellares, O’Shea, Diarmuid , Murphy, D.J., Fabre, Aurélie , Forde, Sarah H. , Diesler, Rémi , Ryu, Jay H. , Bonella, Francesco , Cottin, Vincent , Taillé, Camille , McCormack, Francis X. , Gupta, Nishant , Strosberg, Jonathan , Lococo, Filippo , Harari, Sergio , Bouros, Demosthenes , Dimeas, Ilias E. , Torres, J. Sellares, Spagnolo, Paolo , Franciosi, Alessandro N. , Crowley, Rachel Katherine , O’Toole, Dermot , Byrne, Adam J. , Keane, Michael P. , Fournel, Ludovic , McCarthy, Cormac

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1804-A1804

10.1164/ajrccm.2025.211.abstracts.a1804 Get It

Abstract Rationale: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a pulmonary condition characterised by neuroendocrine cell proliferation along respiratory bronchioles resulting in tumourlet formation which may progress to pulmonary carcinoid. DIPNECH is a rare and under-recognised condition that predominantly affects females, with an estimated worldwide incidence of 5-6 people per million population. Given it's rarity and the poor understanding around the pathogenesis and treatment of this condition, we undertook the largest international case series to date of DIPNECH patients. We aim to further characterise this patient cohort to better understand the clinical features, identify common pulmonary function test (PFT) patterns and radiographic findings and describe current treatment practices. Methods: We collated data from 17 centres across 8 different countries comprising a total of 258 patients. Data collected included patient demographics, smoking history, symptoms, co-morbidities, pathological diagnosis, imaging findings, PFT pattern and therapies. Results: In total 258 patients were identified. The median age was 65 (SD+/- 10.6). 241 (93%) were female. 39% (n= 94/243) were ex-smokers. 79% (n=186/234) of patients reported pulmonary symptoms with cough being the most common symptom reported in 81% (n=151/186) of patients. Many patients were polysymptomatic, with cough and dyspnoea being the most common combination of symptoms described. (50.54%; n=94/186). Complete spirometry pattern was documented for 180 patients (69.78%) with an obstructive pattern being the most commonly observed (n=76/180; 42%). 27.5% (n=41/139) had clinically significant FEV1 reversibility post bronchodilator administration. Pathology specimens were available in 219 cases. Most common pathological features were neuroendocrine hyperplasia which was observed in 75% (n=165/219) and tumourlets in 74% (n=162/219) of cases. Carcinoid, either typical or atypical, was observed in 64% (n=141/219) of samples. 252 patients had computed tomography (CT) imaging performed. Pulmonary nodules were the most common feature identified in 99.60% of cases (248/250). Mosaic attenuation (69.30%; n=50/173) and airway dilatation (28.90%; n=50/173) were also frequently reported. There was no significant correlation between symptoms (cough, dyspnoea, wheeze) and airway dilatation (p=0.496), mosaic attenuation (p=0.496) and PFT pattern (p=0.837). There was a significant association between presence of symptoms and mosaic attenuation on CT (p=0.003). Conclusions: DIPNECH, while a rare disorder, is understudied. This international case series is the largest performed to date and highlights the complexity in management of these patients.
Echocardiographic nomograms in children living at high altitude according to sex
Mekonnen, Demeke, Ren, Ben , Mercado, Jorge, Kurmann, Reto , Zürcher, Fabian, Krähenmann, Peter, Llerena, Nassip , Torres, Pedro Iturralde , Pilgrim, Thomas , Spitzer, Ernest , Ren, Claire B , Pilgrim, Thomas , Spitzer, Ernest , Garcia-Ruiz, Victoria , Torres, Pedro

Mayo Clinic

European Heart Journal - Imaging Methods and Practice | May 5, 2025 | Volume: 3 | Issue: 1 | Pages: No page available

10.1093/ehjimp/qyaf053 | PMID 40416836 Get It

Abstract Aims This study aimed to establish 2D and M-mode echocardiographic reference values for cardiac chambers, outflow tracts, and great vessels for school children living at high altitudes, differentiated between males and females. Methods and results This post hoc analysis included children with normal echocardiography from a cluster randomized cross-sectional survey of rheumatic heart disease among school children in Peru. The echocardiograms were acquired with a portable machine and the images were analysed centrally with a standardized methodology. Body surface area (BSA) was used as an independent variable to predict the mean values of echocardiographic measurements for both male and female groups. Reference values are presented on z-scores and nomograms based on sex. Propensity score matching was used to compare sexes. A total of 985 students aged 5–16 years were included. The Haycock formula provided the best fit and was used when presenting data as predicted values for a given BSA. The z-score and nomograms for all essential parameters of cardiac chambers, great vessels, and functional surrogates are presented based on sex. The majority of the parameters were significantly different per sex after propensity score matching. Conclusion Normal reference values and nomograms of cardiac chambers, outflow tracts, and great arteries in healthy school children living at high altitudes based on sex were reported. These data partly addressed the existing gaps in paediatric echocardiographic nomograms.
Abstract 2787: Effect of miR-494 modulation in colorectal cancer (CRC): Clinical outcome, target expression and cell characteristics
Millstein, Joshua , Ashouri, Karam , Algaze, Sandra, Yang, Yan , Gonzalez, Lesly Torres, Shah, Unnati Hemant, Zhang, Wu , Lenz, H., Torres‐Gonzalez, Lesly , Mittal, Pooja , Soni, Shivani , Battaglin, Francesca , Algaze, Sandra , Jayachandran, Priya , Yang, Yan , Ou, Fang‐Shu , Venook, Alan P. , Singh, Indrakant Kumar

Mayo Clinic

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2787-2787

10.1158/1538-7445.am2025-2787 Get It

Background. MicroRNAs are small, single-stranded non-coding RNA molecules that play major role in gene regulation. miRNAs have been reported as both tumor suppressive and oncogenic and are promising candidates for cancer prognosis and treatment. miR-494 is known to promote cell migration and invasion in CRC. Our study aimed to further explore the role of miR-494 modulation (inhibition and overexpression) in CRC. Methods. We evaluated the impact of tumor gene expression of MIR494 on outcomes (overall survival: OS; progression-free survival: PFS) in data for 433 metastatic CRC (mCRC) patients (pts) (bevacizumab [bev] (N = 226) vs cetuximab [cet] (N = 207)) enrolled in randomized phase III CALGB/SWOG 80405 trial obtained from Alliance for Clinical Trials in Oncology. RNA extracted from FFPE tumor samples was sequenced using the HiSeq 2500 (Illumina). Gene expression was divided into high, medium and low. Associations were assessed by log-rank test and multivariable Cox proportional hazards regression model. Treatment-gene interactions were analyzed using the likelihood ratio test. CRC cell lines HCT116 and HT29 were transfected with miR-494 inhibitors and mimics for 48 hours and total RNA was collected, followed by RT-qPCR (miR-494 and target genes BMAL1, PAK1, CDH1, CDH2, SNAI1, TWIST) and clonogenic assays. Results. High miR-494 was significantly associated with worse PFS in overall (median survival: high vs low: 9.3 vs 11.3 months, P&lt;0.025) and cet-treated (median survival high vs low: 9.2 vs 9.6 months, P&lt;0.025) mCRC cohorts, while no significance was observed in bev-treated mCRC. Multivariable Cox model showed significant association between high miR-494 and worse PFS and OS in the cet-treated cohort; however, treatment-gene interaction was not statistically significant. Expression analysis revealed miR-494 was significantly reduced and increased following inhibitor and mimic transfection, respectively. Differential gene expression of the target genes analyzed was observed between the miR-494 inhibitor and mimic-treated HCT116 and HT29 samples. In HCT116 cells, inhibition of miR-494 significantly (P &lt; 0.01) reduced expression of PAK1, while increased the expression of CDH1. The number of colonies formed relatively increased after transfection with miR-494 inhibitor compared to miR-494 mimic. Conclusion. Our findings showed that high miR-494 expression correlated with worse PFS overall and in cet-treated mCRC pts. It would be interesting to check for potential associations with EGFR signaling (direct or indirect). Further studies are warranted for efficient targeting and to gain better understanding of the associated signaling involved in miR-494 modulation in CRC. Support: U10CA180821, U10CA180882; U10CA180888 (SWOG): Genentech. https://acknowledgments.alliancefound.org; P30CA014089, UG1CA180830 [HJL]. Clinicaltrials.gov Identifier: NCT00265850 Citation Format: Pooja Mittal, Joshua Millstein, Shivani Soni, Francesca Battaglin, Karam Ashouri, Sandra Algaze, Priya Jayachandran, Yan Yang, Lesly T. Gonzalez, Unnati H. Shah, Wu Zhang, Fang-Shu Ou, Alan P. Venook, Indrakant K. Singh, Heinz J. Lenz. Effect of miR-494 modulation in colorectal cancer (CRC): Clinical outcome, target expression and cell characteristics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2787.
Abstract 2282: Genetic architecture of breast cancer across diverse populations: Assessing heritability, genetic correlation, and polygenicity
Williams, Jacob , Jahagirdar, Om , Li, Jingmei, Godbole, Devika , Dorling, Leila , Dennis, Joe, Kushi, Larry, Carvajal‐Carmona, Luis G. , Haiman, Christopher A. , Zheng, Wei , Huo, Dezheng , Easton, Douglas F. , Chatterjee, Nilanjan , Kraft, Peter, Wong, W. W., Zhu, Qianqian , Ahearn, Thomas U., Li, James , Zanti, Maria , Jia, Guochong , Hu, Qiang , Brandenburg, Jean‐Tristan , Li, Yàn , Ho, Weang-Kee , Miranda, Patricio , Dias, Julie‐Alexia , Chen, Wenlong Carl , Boddicker, Nicholas , Wang, Ying , Martin, Alicia R. , Zhang, Martin Jinye , Zhang, Yan , John, Esther M. , Torres-Mejı́a, Gabriela , Kushi, Larry, Weitzel, Jeffrey N. , Neuhausen, Susan L. , Ziv, Elad , Fejerman, Laura , Chatterjee, Nilanjan , García‐Closas, Montserrat , Wong, Wendy, Michailidou, Kyriaki , Dutta, Diptavo , Ahearn, Thomas U. , Zhang, Haoyu

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2282-2282

10.1158/1538-7445.am2025-2282 Get It

Abstract Introduction: Breast cancer genome-wide association studies (GWAS) have identified over 200 susceptibility loci, many replicated in diverse populations. However, cross-ancestry evaluation of breast cancer genetic architecture remains limited. We examined breast cancer genetic architecture using GWAS summary results from European (EUR; cases (ca) = 188,474, controls (co) = 96,201), East Asian (EAS; ca = 20,393, co = 86,329), African American (AA; ca = 9,235, co = 10,184), and US Hispanic/Latina and Latin American (H/L; ca = 2,396, co =7,468) studies. Methods: GWAS results were derived from the Breast Cancer Association Consortium, the African Ancestry Breast Cancer Genetics Consortium (AABCG), Biobank Japan, and a meta-analysis of five studies of H/L women with breast cancer. Linkage disequilibrium (LD) scores were generated for EUR, EAS, and AMR using the 1000 Genomes Project, while AA LD scores were derived from a subset of AABCG controls. Heritability was estimated for each ancestry group using LD score regression. Genetic correlations between populations were assessed via Popcorn. Polygenicity was analyzed using GENESIS; however, due to the limited sample size in the H/L studies, these estimates were restricted to AA, EAS, and EUR. Enrichment of heritability across regulatory elements was evaluated using stratified LD score regression across all populations. Results: The logit-scale heritability and corresponding standard error (SE) were 0.466 (0.066) for EAS, 0.501 (0.050) for EUR, 0.588 (0.360) for H/L, and 0.614 (0.095) for AA. The estimated number of independent susceptibility loci was 4,446 for EAS, 5,235 for EUR, and 8,308 for AA. Using a clumping and thresholding approach, an optimal set of common variants were projected to explain 38.6% (EUR), 39.4% (EAS), and 26.2% (AA) of genetic variance for samples of 100,000 cases and 100,000 controls with AUCs from corresponding estimated polygenic risk scores (PRSs) of 0.621 (EUR), 0.634 (EAS), and 0.611 (AA). Genetic correlations were strongest between EUR and EAS (ρ = 0.79, SE = 0.08) and EUR and H/L (ρ = 0.68, SE = 0.21), and weakest between AA and EAS (ρ = 0.42, SE = 0.14) and AA and H/L (ρ = 0.26, SE = 0.24). Among 73 genomic features, we found significant (P &lt; 0.05/73) enrichment in heritability in EUR for ‘ancient promoter’ regions, transcription factor binding sites, H3K4me3, ‘super-enhancers’, H3K4me1, H3K27ac; in EAS for ‘super-enhancers’; and in AA for H3K27ac. No genomic features were significantly enriched in H/L, likely due to limited power. Conclusion: These findings suggest a shared breast cancer genetic architecture across diverse populations, as well as the potential for a similar level of breast cancer risk stratification by PRS in these populations. Expanding GWAS in underrepresented populations is essential to improve genetic risk predictions and foster equitable cancer prevention. Citation Format: James L. Li, Maria Zanti, Jacob Williams, Om Jahagirdar, Guochong Jia, Qiang Hu, Jean-Tristan Brandenburg, Li Yan, Weang-Kee Ho, Jingmei Li, José P. Miranda, Devika Godbole, Julie-Alexia Dias, Leila Dorling, Wenlong C. Chen, Nicholas Boddicker, Ying Wang, Alicia Martin, Martin J. Zhang, Yan Zhang, Joe Dennis, Esther M. John, Gabriela Torres-Mejia, Larry Kushi, Jeffrey Weitzel, Susan L. Neuhausen, Luis Carvajal-Carmona, Christopher Haiman, Elad Ziv, Laura Fejerman, Wei Zheng, Dezheng Huo, Douglas Easton, Nilanjan Chatterjee, Peter Kraft, Montserrat Garcia-Closas, Wendy Wong, Kyriaki Michailidou, Qianqian Zhu, Diptavo Dutta, Thomas U. Ahearn, Haoyu Zhang. Genetic architecture of breast cancer across diverse populations: Assessing heritability, genetic correlation, and polygenicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2282.